Pharmacokinetic parameters
|
Fosmidomycin monotherapy (N = 15)
|
Fosmidomycin + Clindamycin (N = 18)
|
---|
| |
Fosmidomycin
|
Clindamycin
|
Cmax (μg/ml)
|
4.58 (2.32–6.77)
|
5.86 (2.79–12.52)
|
7.34 (4.88–12.73)
|
tmax (hr)
|
2 (1–4)
|
2 (1–4)
|
1 (1–2)
|
Ctrough-obs (μg/ml)
|
1.90 (0.92–2.99)
|
0.40 (0.0–2.01)
|
1.32 (0.39–3.42)
|
Cmin-ave (μg/ml)
|
1.47 (0.06–9.96)
|
1.06 (0.20–2.98)
|
0.17 (0.01–0.78)
|
Cmax-ave (μg/ml)
|
7.22 (1.52–15.84)
|
8.67 (4.21–14.23)
|
6.63 (3.96–9.52)
|
Css-ave (μg/ml)
|
3.74 (3.18–12.52)
|
2.93 (1.97–6.98)
|
1.91 (1.20–3.06)
|
Fluctuation
|
5.1 (1.6–47.6)
|
10.5 (3.6–40.3)
|
1.1 (0.7–1.6)
|
AUC0, t (μg.hr/ml)
|
22.91 (12.65–33.32)
|
35.00 (20.41–78.90)
|
31.80 (15.84–370.67)
|
AUC0,((μg.hr/ml)
|
29.7 (25.06–100.16)
|
39.13 (24.29–85.55)
|
31.91 (19.28–50.49)
|
λ Z (/hr
|
0.201 (0.06–0.48)
|
0.196 (0.107–0.308)
|
0.272 (0.156–0.464)
|
T1/2z (/hr)
|
3.4 (1.4–11.8)
|
3.5 (2.2–6.5)
|
2.6 (1.5–4.4)
|
VZ/F (l)
|
211.40 (96.84–823.04)
|
116.21 (69.94–267.45)a
|
67.50 (46.56–135-87)
|
CL/F (l/hr)
|
40.08 (11.97–47.18)
|
25.94 (10.74–38.13)b
|
18.77 (11.77–30.12)
|
- a = Statistically significant difference with monotherapy with p-value = 0.004
- b = Statistically significant difference with monotherapy with p-value < 0.0001